ISSN: 1078-0432

Clinical Cancer Research Q1 Unclaimed

American Association for Cancer Research Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials It has an SJR impact factor of 4.399.

Clinical Cancer Research focuses its scope in these topics and keywords: cancer, receptor, factor, growth, patients, prostate, therapeutic, lung, human, response, ...

Type: Journal

Type of Copyright: CC BY-NC-ND

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Oncology (Q1)

Price

3500 €

Inmediate OA

NPD

Embargoed OA

1500 €

Non OA

Metrics

4.399

SJR Impact factor

344

H Index

764

Total Docs (Last Year)

2137

Total Docs (3 years)

28826

Total Refs

26331

Total Cites (3 years)

2062

Citable Docs (3 years)

11.69

Cites/Doc (2 years)

37.73

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Cancer Cell Q1
Journal of Clinical Oncology Q1
Annals of Oncology Q1
JAMA oncology Q1
Molecular Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer

External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group

Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy

Combined Inhibition of Both p110a and p110beta Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer

Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2

Expression of Matrix Metalloproteinase-9 in Head and Neck Squamous Cell Carcinoma: A Potential Marker for Prognosis

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

Circulating Matrix Metalloproteinase-9 Levels as a Biomarker of Disease

Interleukin-21 Signaling: Functions in Cancer and Autoimmunity

Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition

SHOW MORE ARTICLES

Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas

Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials

Failures in Phase III: Causes and Consequences

Significant Effect of Polymorphisms in

Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma

Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas

Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials